VENUS®
Enjoy Innovations

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2014

(Amt. Rs. in million)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended on
	Part – I	30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from operations						
	Gross Sales	1254.85	1210.55	1246.96	2465.40	2515.75	5,195.44
	Less : Excise Duty	1.10	2.42	1.68	3.52	4.02	8.54
	(a) Net Sales	1253.75	1208.13	1245.28	2461.88	2511.73	5,186.90
	(b) Other Operating Income	5.76	6.66	7.15	12.42	12.78	73.65
	Total Income from Operation (Net)	1259.51	1,214.79	1,252.43	2474.30	2,524.51	5260.55
2	Expenses						
	(a) Consumption of raw materials	783.75	629.42	704.12	1413.17	1456.62	3,012.81
	(b) (Increase)/ Decrease in stock in trade	1.31	49.12	22.51	50.43	19.71	-23.22
	(c) Employee benefits expense	68.99	63.42	59.66	132.41	118.83	255.65
	(d) Depreciation & amortisation expense	82.29	111.30	96.87	193.59	192.22	386.09
	(e) Other expenses	138.24	176.45	142.15	314.69	289.29	683.03
	Total expense	1074.58	1,029.71	1,025.31	2104.29	2,076.67	4314.36
3	Profit from operations before other income , finance costs and exceptional items (1-2)	184.93	185.08	227.12	370.01	447.84	946.19
	EBIDTA (3+2(d))	267.22	296.38	323.99	563.60	640.06	1332.28
4	Other income	1.12	1.00	0.21	2.12	8.39	4.06
5	Profit before finance costs and exceptional items (3+4)	186.05	186.08	227.33	372.13	456.23	950.25
6	Finance Costs	83.01	83.59	69.21	166.60	136.02	292.93
7	Profit after finance costs but before exceptional items (5-6)	103.04	102.49	158.12	205.53	320.21	657.32
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit from ordinary activities before tax (7+8)	103.04	102.49	158.12	205.53	320.21	657.32
10	Tax expense	0.00	0.00	8.15	0.00	17.12	47.82
11	Profit from ordinary activities after tax (9-10)	103.04	102.49	149.97	205.53	303.09	609.50
12	Exceptional items (net of tax expense	0.00	00.00	00.00	0.00	0.00	0.00
13	Net profit for the period (11-12)	103.04	102.49	149.97	205.53	303.09	609.50
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	4,559.73
16	E.P.S - Basic not annualised for the qtr	9.01	8.96	13.11	17.96	26.49	54.19
	- Annualised	36.02	35.84	52.43	35.93	52.98	54.19
	Part – II						
1	Public Shareholding						
	- Number of Shares	7520988	7154551	6437086	7520988	6437086	6437086
	- Percentage of Shareholding	65.73	62.53	56.26	65.73	56.26	56.26
2	Promoters and promoter group shareholding						
	a) Pledged as collateral security to bank						
	- Number of Shares	1330000	1937250	1930000	1330000	1930000	2080000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	33.92	45.18	38.56	33.92	38.56	41.56
	- Percentage of shares (as a % of the total share capital	11.62	16.93	16.87	11.62	16.87	18.18
	b) Non-Encumbered						
	- Number of Shares	2591000	2350187	3074902	2591000	3074902	2924902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	66.08	54.82	61.44	66.08	61.44	58.44
	- Percentage of shares (as a % of the total share capital	22.65	20.54	26.87	22.65	26.87	25.56

Particulars	Quarter ended 30.09.2014
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	2
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	2

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS®
Enjoy Innovations

Standalone Statement of Assets and Liabilities

	Particulars	Half Year Ended on	Year Ended on
		30/09/2014	31/03/2014
A	EQUITY AND LIABILITIES	(₹ In Millions)	(₹ In Millions)
1	**Shareholders' funds**		
	(a) Share capital	114.42	114.42
	(b) Reserves and surplus	4765.27	4559.74
	Sub-total – Shareholders' funds	4879.69	4674.16
2	**Non-current liabilities**		
	(a) Long-term borrowings	1657.56	1395.06
	(b) Deferred tax liabilities (net)	177.85	177.85
	(c) Other long-term liabilities	6.79	6.69
	(d) Long-term provisions	36.14	33.14
	Sub-total – Non-current liabilities	1878.34	1612.74
3	**Current liabilities**		
	(a) Short-term borrowings	1124.38	1100.77
	(b) Trade payables	264.16	281.41
	(c) Other current liabilities	149.25	546.01
	(d) Short-term provisions	49.00	145.12
	Sub-total – Current liabilities	1586.79	2073.31
	TOTAL – EQUITY AND LIABILITIES	8344.82	8360.21
B	**ASSETS**		
1	**Non-current assets**		
	(a) Fixed assets	4939.213	4838.89
	(b) Non-current investments	287.36	287.36
	(c) Long-term loans and advances	592.79	549.82
	Sub-total – Non-current assets	5819.36	5676.07
2	**Current assets**		
	(a) Current investments		
	(b) Inventories	1397.28	1414.56
	(c) Trade receivables	638.29	628.04
	(d) Cash and cash equivalents	37.84	43.82
	(e) Short-term loans and advances	452.05	597.72
	Sub-total – Current assets	2525.46	2684.14
	TOTAL – ASSETS	8344.82	8360.21

For VENUS REMEDIES LIMITED

VENUS®
Enjoy Innovations

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on November 14, 2014.

2. During the Quarter:

a) Venus Remedies received its first marketing authorization in SWITZERLAND from Swiss drug authority (SWISSMEDIC) for Gemcitabine.

b) Venus has entered into collaborative agreement with TEVA Canada for an Upcoming Anti Cancer Drug.

c) Venus has entered into distribution cum outlicensing agreement with Mylan for marketing meropenem in three European countries".

d) Venus has entered Singapore's topical pain management market with a marketing authorisation and patent for its herbal nanotechnology-based pain reliever Trois

3. Investor Complaints pending during the beginning of the quarter-NIL, Received during the quarter-two, Disposed of during the quarter-NIL, Remaining unresolved at the end of the quarter-two

4. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

(Pawan Chaudhary)
Chairman & Managing Director

Date : 14.11.2014

VENUS®
Enjoy Innovations

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2014

(Amt. Rs. in million)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended on
	Part – I	30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from operations						
	Gross Sales	1254.85	1210.55	1246.96	2465.40	2515.75	5,195.44
	Less : Excise Duty	1.10	2.42	1.68	3.52	4.02	8.54
	(a) Net Sales	1253.75	1208.13	1245.28	2461.88	2511.73	5,186.90
	(b) Other Operating Income	5.76	6.66	7.15	12.42	12.78	73.65
	Total Income from Operation (Net)	1259.51	1,214.79	1,252.43	2474.30	2,524.51	5260.55
2	Expenses						
	(a) Consumption of raw materials	783.75	629.42	704.12	1413.17	1456.62	3,012.81
	(b) (Increase)/ Decrease in stock in trade	1.31	49.12	22.51	50.43	19.71	-23.22
	(c) Employee benefits expense	68.99	63.42	59.66	132.41	118.83	255.65
	(d) Depreciation & amortisation expense	82.29	111.30	96.87	193.59	192.22	386.09
	(e) Other expenses	138.24	176.45	142.15	314.69	289.29	683.03
	Total expense	1074.58	1,029.71	1,025.31	2104.29	2,076.67	4314.36
3	Profit from operations before other income , finance costs and exceptional items (1-2)	184.93	185.08	227.12	370.01	447.84	946.19
	EBIDTA (3+2(d))	267.22	296.38	323.99	563.60	640.06	1332.28
4	Other income	1.12	1.00	0.21	2.12	8.39	4.06
5	Profit before finance costs and exceptional items (3+4)	186.05	186.08	227.33	372.13	456.23	950.25
6	Finance Costs	83.01	83.59	69.21	166.60	136.02	292.93
7	Profit after finance costs but before exceptional items (5-6)	103.04	102.49	158.12	205.53	320.21	657.32
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit from ordinary activities before tax (7+8)	103.04	102.49	158.12	205.53	320.21	657.32
10	Tax expense	0.00	0.00	8.15	0.00	17.12	47.82
11	Profit from ordinary activities after tax (9-10)	103.04	102.49	149.97	205.53	303.09	609.50
12	Exceptional items (net of tax expense	0.00	00.00	00.00	0.00	0.00	0.00
13	Net profit for the period (11-12)	103.04	102.49	149.97	205.53	303.09	609.50
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	4,559.73
16	E.P.S - Basic not annualised for the qtr	9.01	8.96	13.11	17.96	26.49	54.19
	- Annualised	36.02	35.84	52.43	35.93	52.98	54.19
	Part – II						
1	Public Shareholding						
	- Number of Shares	7520988	7154551	6437086	7520988	6437086	6437086
	- Percentage of Shareholding	65.73	62.53	56.26	65.73	56.26	56.26
2	Promoters and promoter group shareholding						
	a) Pledged as collateral security to bank						
	- Number of Shares	1330000	1937250	1930000	1330000	1930000	2080000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	33.92	45.18	38.56	33.92	38.56	41.56
	- Percentage of shares (as a % of the total share capital	11.62	16.93	16.87	11.62	16.87	18.18
	b) Non-Encumbered						
	- Number of Shares	2591000	2350187	3074902	2591000	3074902	2924902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	66.08	54.82	61.44	66.08	61.44	58.44
	- Percentage of shares (as a % of the total share capital	22.65	20.54	26.87	22.65	26.87	25.56

Particulars	Quarter ended 30.09.2014
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	2
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	2

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR